BBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BridgeBio Pharma's share price is $36.74. BridgeBio Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $1.24. Hence, BridgeBio Pharma's PS Ratio for today is 29.68.
The historical rank and industry rank for BridgeBio Pharma's PS Ratio or its related term are showing as below:
During the past 8 years, BridgeBio Pharma's highest PS Ratio was 1015.86. The lowest was 12.57. And the median was 83.10.
BridgeBio Pharma's Revenue per Sharefor the three months ended in Dec. 2024 was $0.03. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $1.24.
During the past 12 months, the average Revenue per Share Growth Rate of BridgeBio Pharma was 1993.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 35.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 15.70% per year.
During the past 8 years, BridgeBio Pharma's highest 3-Year average Revenue per Share Growth Rate was 35.20% per year. The lowest was -6.60% per year. And the median was 10.90% per year.
The historical data trend for BridgeBio Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma Annual Data | |||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
PS Ratio | Get a 7-Day Free Trial | 1,015.86 | 34.53 | 14.46 | 708.25 | 23.00 |
BridgeBio Pharma Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
PS Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
708.25 | 25.22 | 20.63 | 20.92 | 23.00 |
For the Biotechnology subindustry, BridgeBio Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
BridgeBio Pharma's PS Ratio for today is calculated as
PS Ratio | = | Share Price | / | Revenue per Share (TTM) |
= | 36.74 | / | 1.238 | |
= | 29.68 |
BridgeBio Pharma's Share Price of today is $36.74.
BridgeBio Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.24.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PS Ratio | = | Market Cap | / | Revenue |
The Revenue here is for the trailing 12 months.
BridgeBio Pharma (NAS:BBIO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Thank you for viewing the detailed overview of BridgeBio Pharma's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Hannah Valantine | director | 1305 O'BRIEN DRIVE, MENLO PARK CA 94025 |
Kkr Genetic Disorder L.p. | 10 percent owner | C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019 |
Neil Kumar | director, officer: See Remarks | C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304 |
Brian C Stephenson | officer: See Remarks | 3160 PORTER DR, STE 250, PALO ALTO CA 94304 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Randal W Scott | director | 171 MAIN STREET #225, LOS ALTOS CA 94022 |
Frank Mccormick | officer: Chairman of Oncology | C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001 |
Viking Global Opportunities Parent Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Douglas A. Dachille | director | 175 WATER STREET, NEW YORK NY 10038 |
Andrew Lo | director | C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142 |
Ronald J Daniels | director | C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901 |
Fred Hassan | director | C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487 |
James C Momtazee | director | 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025 |
Brent L Saunders | director | 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033 |
Andrea Ellis | director | C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301 |
From GuruFocus
By Marketwired • 02-20-2025
By GuruFocus News • 02-11-2025
By Marketwired • 12-13-2024
By GuruFocus News • 01-13-2025
By GuruFocus News • 01-08-2025
By GuruFocus News • 02-21-2025
By GuruFocus News • 02-13-2025
By Marketwired • 11-12-2024
By Marketwired • 11-23-2024
By Marketwired • 03-17-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.